TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11148512

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (IB) 250 microg combined with 2.5 mg albuterol by jet nebulization.
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (IB) for children >6 years (N = 70).
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo group received isotonic saline solution substituted for IB.
Number of subjects: 210
Study: 9351559

Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: PSA in combination with digital rectal examination
Number of subjects: 30000
Study: 7513718

Group type: EXPERIMENTAL
Intervention: 12-h iv GH infusion (1 IU/h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2-day sc GH treatment (8 IU/day) followed by 12-h iv infusion of GH (1 IU/h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Regular daily sc GH therapy (3 IU/m2.day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 12-h iv saline infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: No GH (after discontinuation of GH for 2 days)
Number of subjects: 14
Study: 3284975

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) plus fluoxymesterone (FLU)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Fluoxymesterone (FLU) following TAM
Number of subjects: 238
Study: 30683087

Group type: EXPERIMENTAL
Intervention: Training package for tobacco cessation support for TB health workers (interactive two-day training)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: COM-B questionnaire administered to TB health workers
Number of subjects: 36
Study: 27840330

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (30 mg IV bolus and 1 mg/kg subcutaneous dose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 25
Study: 25724860

Group type: EXPERIMENTAL
Intervention: Nebulized colistin 1 million IU twice a day for one year
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nebulized colistin
Number of subjects: 39
Study: 23012159

Group type: EXPERIMENTAL
Intervention: Telephone-delivered secondary prevention program
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 430
Study: 21952357

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 18334782

Group type: EXPERIMENTAL
Intervention: Ropivacaine (7.5 mg/ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% without an additive
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with an adrenaline additive (1:200,000)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline solution (placebo)
Number of subjects: 20
Study: 16551149

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 100
Study: 15153823

Group type: EXPERIMENTAL
Intervention: Class 1 compression stockings (10‐15 mmHg at the ankle)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Reference stockings of identical appearance
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Class 1 compression stockings
Number of subjects: 125
Study: 10984373

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Budesonide nasal spray and Placebo
Number of subjects: 30
Study: 8799514

Group type: COMPARATOR
Intervention: 619C89 (0.5, 1, 1.5, 2, 2.5 mg kg‐1 loading infusions followed by 0.25, 0.5, 0.75, 1, 1.25 mg kg‐1 maintenance infusions)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 619C89
Number of subjects: 48
Study: 1847648

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with cyclophosphamide (10 G m‐2), ifosfamide (11 G m‐2), mitomycin C (70 mg m‐2), mustine (30 mg m‐2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: High dose chemotherapy with cisplatin (100 mg m‐2), ifosfamide (11 G m‐2), mitomycin C (70 mg m‐2), mustine (30 mg m‐2)
Number of subjects: 23
Study: 6335905

Group type: EXPERIMENTAL
Intervention: Bone Gla-protein (BGP) levels in LT-ROD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bone Gla-protein (BGP) levels in HT-ROD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of BGP with parathyroid hormone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of BGP with alkaline phosphatase
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of BGP with cellular and non-cellular parameters of bone formation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of BGP with histologic parameters of bone
Number of subjects: 30
Study: 31462554

Group type: EXPERIMENTAL
Intervention: Stop NA therapy for 72 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Continue NA therapy for 72 weeks
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Stop NA therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Continue NA therapy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 30150460

Group type: EXPERIMENTAL
Intervention: 750 mg MEDI8852 plus 75 mg oseltamivir
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 3,000 mg MEDI8852 plus 75 mg oseltamivir
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 3,000 mg MEDI8852 alone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo plus 75 mg oseltamivir
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All MEDI8852 cohorts combined
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oseltamivir only (cohort 3)
Number of subjects: 126
Study: 27793183

Group type: EXPERIMENTAL
Intervention: Cognitive training (COG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Physical exercise training (PE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sequential training (SEQ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dual-task training (DUAL)
Number of subjects: 80
Study: 25297614

Group type: EXPERIMENTAL
Intervention: 1.0 g/d L-tryptophan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2.0 g/d L-tryptophan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 3.0 g/d L-tryptophan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 4.0 g/d L-tryptophan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5.0 g/d L-tryptophan
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (0 g/d)
Number of subjects: 17
Study: 22446172

Group type: EXPERIMENTAL
Intervention: Benfotiamine (300 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 20158623

Group type: EXPERIMENTAL
Intervention: Lifestyle factors including diet eating habits
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Lifestyle factors including resting and sleeping habits
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Lifestyle factors including drug usage patterns
Number of subjects: 170

Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 170

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 170

Group type: COMPARATOR
Intervention: Stress levels
Number of subjects: 170
Study: 18310585

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual vocational rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPS service characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Service uptake
Number of subjects: 0
Study: 15678299

Group type: EXPERIMENTAL
Intervention: Open kinetic chain (OKC) knee extensor resistance training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Closed kinetic chain (CKC) knee extensor resistance training
Number of subjects: 49
Study: 11943441

Group type: EXPERIMENTAL
Intervention: Standard spirometer (Renaissance spirometry system) with quality assurance program
Number of subjects: 2859
Study: 10422925

Group type: EXPERIMENTAL
Intervention: Preoperative autologous donation (3 U autologous blood)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: rHuEPO plus ANH (600 U/kg rHuEPO at 21 and 14 days before surgery and 300 U/kg on day of surgery followed by ANH)
Number of subjects: 79

Group type: COMPARATOR
Intervention: ANH (blinded, placebo injections)
Number of subjects: 79

Group type: COMPARATOR
Intervention: ANH
Number of subjects: 79
Study: 7578656

Group type: EXPERIMENTAL
Intervention: All-night sleep EEG spectral analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 0
Study: 2104081

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) maintenance therapy (120 mg Bi2O3, one swallow tablet nocte)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 71
Study: 692577

Group type: EXPERIMENTAL
Intervention: Solution or uncoated tablets
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sustained-release formulations (3 of 6)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sustained-release formulations (3)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Uncoated tablets
Number of subjects: 6
Study: 30917512

Group type: EXPERIMENTAL
Intervention: Palatable comfort meal ingestion
Number of subjects: 24
Study: 28427373

Group type: EXPERIMENTAL
Intervention: Self-help psycho-educational programme 'PERANTARA'
Number of subjects: 106
Study: 25680689

Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 3 grams daily for 3 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 23755929

Group type: EXPERIMENTAL
Intervention: ER tramadol 200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ER tramadol 600 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20934556

Group type: EXPERIMENTAL
Intervention: Edoxaban high exposure (60 mg daily, adjusted for drug clearance)
Number of subjects: 20500

Group type: EXPERIMENTAL
Intervention: Edoxaban low exposure (30 mg daily, adjusted for drug clearance)
Number of subjects: 20500

Group type: COMPARATOR
Intervention: Warfarin titrated to an international normalized ratio of 2.0 to 3.0
Number of subjects: 20500

Group type: EXPERIMENTAL
Intervention: Edoxaban (both high and low exposure)
Number of subjects: 20500
Study: 18574393

Group type: EXPERIMENTAL
Intervention: CBEP + PL
Number of subjects: 315

Group type: COMPARATOR
Intervention: CBEP
Number of subjects: 315
Study: 16630367

Group type: EXPERIMENTAL
Intervention: Activity Monitor (AM)
Number of subjects: 11
Study: 14602878

Group type: EXPERIMENTAL
Intervention: Radio-frequency catheter ablation of accessory pathways
Number of subjects: 224

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 224
Study: 10964871

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1616967

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice daily for 7 days)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Metronidazole (400 mg twice daily for 7 days)
Number of subjects: 119
Study: 6369642

Group type: EXPERIMENTAL
Intervention: One-holed cannula
Number of subjects: 3066

Group type: COMPARATOR
Intervention: Two-holed cannula (flexible and rigid)
Number of subjects: 3066

Group type: COMPARATOR
Intervention: Three other cannulae groups (not specified)
Number of subjects: 3066
Study: 31256104

Group type: EXPERIMENTAL
Intervention: Adjustable standing desktop accessory
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard work desk
Number of subjects: 35
Study: 30208601

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (Ca-antagonists)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACE-I)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 98
Study: 27028279

Group type: COMPARATOR
Intervention: Minimal intervention control (leaflets only)
Number of subjects: 5963

Group type: COMPARATOR
Intervention: Minimal intervention control (single session of advice)
Number of subjects: 5963

Group type: COMPARATOR
Intervention: Minimal intervention control (more than one session of advice)
Number of subjects: 5963

Group type: COMPARATOR
Intervention: Increasing intensity of intervention by moving up a category
Number of subjects: 5963

Group type: COMPARATOR
Intervention: Each additional weigh-in
Number of subjects: 5963
Study: 23981048

Group type: EXPERIMENTAL
Intervention: Adapted yoga
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study: 22828694

Group type: EXPERIMENTAL
Intervention: Therapeutic thoracic facet joint nerve blocks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thoracic radiofrequency neurotomy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thoracic intraarticular injections
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Medial branch blocks
Number of subjects: 13
Study: 20499372

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18076259

Group type: EXPERIMENTAL
Intervention: IVT(‐50%DeltaT) recovery
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IVT and IVT(‐50%DeltaT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: V(.‐)O2max values at IAT, IVT(+50%DeltaT), and IVT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: V(r) at IVT(‐50%DeltaT)
Number of subjects: 10
Study: 16164814

Group type: EXPERIMENTAL
Intervention: Healthy Directions-Small Business (HD-SB)
Number of subjects: 3959

Group type: EXPERIMENTAL
Intervention: Healthy Directions-Health Centers (HD-HC)
Number of subjects: 3959
Study: 12011609

Group type: EXPERIMENTAL
Intervention: Nortriptyline (n = 13)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fluoxetine (n = 13)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10449104

Group type: EXPERIMENTAL
Intervention: Lenercept (10, 50, or 100 mg IV every 4 weeks for up to 48 weeks)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (IV every 4 weeks for up to 48 weeks)
Number of subjects: 168
Study: 8960851

Group type: EXPERIMENTAL
Intervention: ramipril (2.5‐5.0 mg/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: atenolol (50‐100 mg/day)
Number of subjects: 105
Study: 1678580

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 12
Study: 6297516

Group type: EXPERIMENTAL
Intervention: Guar gum (6g t.d.s. with meals)
Number of subjects: 19
Study: 30600136

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 0

Group type: COMPARATOR
Intervention: lixisenatide
Number of subjects: 0
Study: 27669447

Group type: EXPERIMENTAL
Intervention: HIIT + SIT
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HIIT + HIITHI
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HIIT + PER
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HIIT (all groups)
Number of subjects: 71
Study: 27858881

Group type: EXPERIMENTAL
Intervention: CRF plus PRF (group B)
Number of subjects: 56

Group type: COMPARATOR
Intervention: CRF only (group A)
Number of subjects: 56
Study: 24576401

Group type: EXPERIMENTAL
Intervention: High-fat, high-carbohydrate (HFHC) meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral lipid-tolerance test meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Healthy breakfast
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All meals
Number of subjects: 6
Study: 22753560

Group type: EXPERIMENTAL
Intervention: Behavioral weight control (BWC) program combined with activity-based peer intervention
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Behavioral weight control (BWC) program combined with aerobic exercise
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both BWC conditions
Number of subjects: 118
Study: 20122250

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant radiotherapy (40 Gy)
Number of subjects: 1
Study: 17986164

Group type: EXPERIMENTAL
Intervention: Active tDCS over M1 (2 mA, 20 minutes for five consecutive days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Active tDCS over DLPFC (2 mA, 20 minutes for five consecutive days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study: 16009004

Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 545

Group type: COMPARATOR
Intervention: Non-invasive treatment
Number of subjects: 545
Study: 11960154

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg/day in 4 divided doses for first 4 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40
Study: 9707026

Group type: EXPERIMENTAL
Intervention: Foscarnet 90 mg/kg every 12 h for 15 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ganciclovir 5 mg/kg every 12 h for 15 days
Number of subjects: 39
Study: 7631132

Group type: EXPERIMENTAL
Intervention: IVR 400 micrograms.kg-1 plus DEC 6 mg.kg-1
Number of subjects: 57

Group type: COMPARATOR
Intervention: DEC 6 mg.kg-1
Number of subjects: 57

Group type: COMPARATOR
Intervention: IVR 400 micrograms.kg-1
Number of subjects: 57
Study: 1947955

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 39
Study: 6119685

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg daily
Number of subjects: 25
Study: 31713733

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F (TwHF) 40-60 mg/day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) 100 mg/day
Number of subjects: 76
Study: 29856176

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine with morphine plus nalbuphine (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine with morphine (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 28859947

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 25982

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25982
Study: 26507175

Group type: EXPERIMENTAL
Intervention: Text-delivered smoking cessation intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 24168638

Group type: EXPERIMENTAL
Intervention: Online personal activity monitor (Gruve Solution™)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 33
Study: 20596858

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 15
Study: 18855089

Group type: EXPERIMENTAL
Intervention: 28-mm metal-on-polyethylene bearing
Number of subjects: 0

Group type: COMPARATOR
Intervention: 28-mm metal-on-metal bearing
Number of subjects: 0

Group type: COMPARATOR
Intervention: 36-mm metal-on-metal bearing
Number of subjects: 0
Study: 17709060

Group type: EXPERIMENTAL
Intervention: Massage therapy (50 min, twice weekly for 4 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Guided relaxation (50 min, twice weekly for 4 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Guided relaxation
Number of subjects: 54
Study: 15468748

Group type: EXPERIMENTAL
Intervention: Web-based survey
Number of subjects: 7000

Group type: COMPARATOR
Intervention: U.S. mail survey
Number of subjects: 7000
Study: 11597532

Group type: EXPERIMENTAL
Intervention: BTA stat test
Number of subjects: 81

Group type: COMPARATOR
Intervention: Voided Urine Cytology (VUC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ureteral Washing Cytology (UWC)
Number of subjects: 81
Study: 9687407

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 50 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 100 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 200 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 600 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 800 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 48
Study: 8021578

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Normotensive subjects
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 33
Study: 2686488

Group type: COMPARATOR
Intervention: Control group (group K) - saline solution
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl (group 0,1F)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 0.2 mg fentanyl (group 0,2F)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 0.3 mg fentanyl (group 0,3F)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 1 mg nifedipine (group 1,0N)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 0.5 mg nifedipine + 0.1 mg fentanyl (group 0,5N + 0,1F)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 1 mg nifedipine + 0.1 mg fentanyl (group 1,0N + 0,1F)
Number of subjects: 140
Study: 326638

Group type: EXPERIMENTAL
Intervention: Metiamide (400 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31632735

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNTA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28339403

Group type: EXPERIMENTAL
Intervention: DaTSCAN (immediate imaging upon diagnosis)
Number of subjects: 20

Group type: COMPARATOR
Intervention: DaTSCAN (delayed imaging at 6 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DaTSCAN (both groups)
Number of subjects: 20